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Abstract 
Literature reports on chronic lymphocytic leukaemia 
(CLL) that show both an elevated familial relative risk 
and familial clustering suggest there is value in 
conducting a genome-wide linkage search on CLL 
families. Our current aim is to ascertain families with 
CLL and to collect blood samples in order to perform a 
genetic linkage study.  
Background  
Approximately 1.3% of males and 1% of females in 
Europe and North America develop leukaemia. CLL is 
the most common of its subtypes, constituting about 
30% of all cases. Its incidence rate increases 
logarithmically from age 35 and has a median age of 
onset of 64 years. No single cytogenetic abnormality or 
gene mutation is found in all CLL cases. However, 
activation of each of the oncogenes BCL1, BCL2 and 
BCL3 has been reported in some cases after detection 
of cytogenetic abnormalities, as has mutation in tumour 
suppressor genes including those associated with the 
mutator phenotype and p53. A putative tumour 
suppressor locus has been identified on chromosome 
13q14.  
A number of case-control and cohort studies have 
examined the cancer risks associated with a family 
history of lymphoproliferative disorders, including 
CLL (Table 1). These studies showed an elevated risk 
of lymphoproliferative disorders in relatives. Although 
no study has systematically examined the incidence of 
leukaemia by specific subtype in cases and relatives, 
there is evidence suggesting that the familial risk of 
leukaemia is greater than the risk of all 
lymphoproliferative disorders. In the cohort study 
reported by Goldgar et al using the Utah population 
database, a 6-fold increase in risk was seen in relatives 
of patients with lymphocytic leukaemia. This database 
comprises over 1.4 million records on a population 
with normal levels of inbreeding that is genetically 
representative of a Northern European population.  
     
Study Cases Relatives Obs Exp 




Leukaemia - First and second degree 7/130 0/130 
Pottern et al., 1991 Chronic lymphocytic 
leukaemia 
Leukaemia - Parents and siblings 13/237 30/1207 
Linet et al., 1989 Chronic lymphocytic 
leukaemia 
Leukaemia - Parents and siblings 25/342 10/342 




Lymphocytic leukaemia - All blood 5/330 2/559 
Giles et al., 1984 Lymphoproliferative 
disorders 
Lympho-proliferative disorders - First 
degree  
35 10.3 
Gunz et al., 1975 Leukaemia Leukaemia - First degree 16 6.61 
Goldgar et al., 1994 Lymphocytic leukaemia Lymphocytic leukaemia - First degree 18 3.6 
Table 1: Familial leukaemia risks 
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Case reports  
There is no doubt from literature reports over 7 decades 
that multiple cases of CLL do occur in families. Two of 
these are illustrated in Figures 1 and 2. Both are 
consistent explicitly or implicitly with vertical 
transmission of an autosomal trait over three 
generations. In Figure 1, the absence of recorded CLL 
in the first two generations is consistent with 
incomplete penetrance.  
Although early reports on familial CLL were published 
before B-cells had been described, most of the 
diagnoses are likely to be accurate. This is because the 
specific morphology of mature B-cell CLL makes 
diagnosis comparatively easy and the generally 
indolent course of the disease contrasts markedly with 
the other leukaemias. We have identified reports that 
describe over 80 pedigrees which show clustering of 
CLL and, sometimes, other lymphoproliferative 
disorders. Some of this literature has been reviewed . 
Of these 80 pedigrees, over a quarter are 
multigenerational CLL families with up to four 
generations, thus illustrating vertical transmission of 
CLL consistent with an autosomal dominant mode of 
inheritance. The majority of families comprise sibs. 
This is not surprising: CLL usually has an indolent 
course and may be asymptomatic for many years, yet it 
also has a late onset. It has been suggested that even 
striking clusters of common cancers could be due to 
ascertainment bias. This is, however, statistical fallacy. 
For example, we have identified reports of 10 sibships 
with three of more affecteds, yet a family with 3 
affected sibs would be expected to occur by chance 
about every 1,000 years.  
Analysis of these reports has also indicated a mean 
decline in age of onset of 21 years (SE = 4.1y) (P = 
0.001) between the affected in the parental generation 
and the affected offspring as well as a reduced 
cumulative disease-free survival period for the 
offspring. Anticipation is now known to arise in a 
dozen instances from single gene defects associated, 
variously, with dominant or recessive modes of 
inheritance.  
Identification of a familial CLL gene would 
significantly help research into the molecular pathology 
and aetiology of CLL. Earlier diagnosis of CLL and 
new approaches to therapy should also follow 
identification of a gene or genes.  
Current progress  
In 1996 we began collecting detailed family histories 
from 130 patients with CLL registered at the Royal 
Marsden Hospital under the care of D.C. In order to 
extend the study, the MRC Adult Leukaemia Working 
Party gave us permission to identify CLL patients in 
MRC trials and contact their consultants (DC is the 
MRC trials co-ordinator). Of the 1402 patients with 
CLL registered in the CLL trials, we have contacted 
and collected family history information on 250 (June 
1997). We have identified 20 families with at least two 
CLL cases. In most of the potentially informative 
families, the affecteds are siblings. We are pursuing a 
further 39 families.  
We initiated this spring an International Co-operative 
Group on Familial CLL under the auspices of the 
International Workshop on CLL with a successful 
satellite meeting of IWCLL. All members of IWCLL in 
32 nations overseas have been contacted and many 
have expressed an interest in contributing. So far, 
around 20 overseas CLL families have been identified 
and blood samples are being collected.  
We have confirmed the finding of anticipation in our 
families and we have published data that does not 
support the claim that germline mutations in the Ataxia 
Telangiectasia confer a particular risk of CLL.  
 
Figure 1. Adapted from McPhedran et al - filled symbols indicate a diagnosis of CLL 
 
Figure 2. Adapted from Furbetta et al - filled symbols indicate a diagnosis of CLL 
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International effort  
The identification of sufficient CLL families to be able 
successfully to perform a genetic linkage study to find 
the CLL gene is a major task. With support from the 
Medical Research Council in the UK and from the 
International Workshop on CLL, the Co-ordinating 
Centre based at the Institute of Cancer Research and 
the Royal Mrsden NHS Trust Hospital in London has 
been able to accrue families from around the world on a 
collaborrative basis. For example, haematologists from 
9 countries contributed families to a paper testing a 
candidate gene, ATM. More detailed genetic 
approaches will become possible as the numbers of 
families contributed increases.  
Clinicians who identify CLL families (i.e. families with 
more than one affected individual) are encouraged to 
advise the Co-ordinating Centre.  
Contact:  
M. R. Yuille MA PhD. Academic Department of 
Haematology and Cytogenetics, Institute of Cancer 
Research, 15 Cotswold Road, SUTTON Surrey SM2 
5NG UK 
OR 
Prof Daniel Catovsky DSc(Med) FRCPath FRCP 
FmedSci. Academic Department of Haematology and 
Cytogenetics, Royal Marsden NHS Trust Hospital, 
Fulham road, London SW3 6JJ 
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